Cipla Limited — Salicylic Exporter Profile
Indian Pharmaceutical Exporter · #3 for Salicylic · $2.0M export value · DGFT Verified
Cipla Limited is the #3 Indian exporter of Salicylic with $2.0M in export value and 121 verified shipments. Cipla Limited holds a 11.7% market share in Salicylic exports across 3 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Salicylic Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Salicylic?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NEW ZEALAND | $1.2M | 89 | 60.6% |
| YEMEN | $334.6K | 9 | 17.0% |
| SRI LANKA | $229.7K | 18 | 11.7% |
| YEMEN, DEMOCRATIC | $211.8K | 5 | 10.8% |
Cipla Limited exports Salicylic to 4 countries. The largest destination is NEW ZEALAND accounting for 60.6% of Cipla Limited's Salicylic shipments, followed by YEMEN (17.0%) and SRI LANKA (11.7%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Salicylic from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| HELLMANN WORLDWIDE LOGISTICS | NEW ZEALAND | $1.2M | 89 |
| CIPLAMEDICA PHARMACEUTICAL INDUSTRI | YEMEN | $208.8K | 6 |
| MEDICA PHARMACEUTICAL INDUSTRIES LI | YEMEN, DEMOCRATIC | $170.2K | 4 |
| MEDICA PHARMACEUTICAL INDUSTRIES L | YEMEN, DEMOCRATIC | $167.3K | 4 |
| BREATHEFREE LANKA PVT LTD | SRI LANKA | $129.5K | 12 |
| TO THE ORDER OF PEOPLES BANK | SRI LANKA | $51.8K | 2 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $48.4K | 4 |
Cipla Limited supplies Salicylic to 7 buyers globally. The largest buyer is HELLMANN WORLDWIDE LOGISTICS (NEW ZEALAND), followed by CIPLAMEDICA PHARMACEUTICAL INDUSTRI (YEMEN) and MEDICA PHARMACEUTICAL INDUSTRIES LI (YEMEN, DEMOCRATIC). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Salicylic Export Value and How Much Does Cipla Limited Contribute?
India exported $12.5M worth of Salicylic through 2,799 shipments from 276 suppliers to 132 countries, serving 632 buyers globally. Cipla Limited contributes $2.0M to this total, accounting for 11.7% of India's Salicylic exports. Cipla Limited ships Salicylic to 4 countries through 7 buyers.
What Is the Average Shipment Value for Cipla Limited's Salicylic Exports?
Cipla Limited's average Salicylic shipment value is $16.3K per consignment, based on 121 shipments totaling $2.0M. The largest destination is NEW ZEALAND (60.6% of Cipla Limited's Salicylic exports).
How Does Cipla Limited Compare to Other Indian Salicylic Exporters?
Cipla Limited ranks #3 among 276 Indian Salicylic exporters with a 11.7% market share. The top 3 exporters are RECKITT BENCKISER (INDIA) PRIVATE LIMITED ($3.6M), RECKITT BENCKISER INDIA PRIVATE LIMITED ($2.2M), CIPLA LIMITED ($2.0M). Cipla Limited processed 121 shipments to 3 destination countries.
What Salicylic Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ASPIN 100 TABLETS (ACETYL SALICYLIC ACID | $113.6K | 8 |
| ASPIN 100 TABLETS ACETYL SALICYLIC ACID | $100.2K | 6 |
| ALSIN-100 TABLETS (ACETYL SALICYLIC ACID 100MG) ( INV. QTY. 14687 PACK 10X30'S= 4406100 NOS ) | $43.6K | 1 |
| ALSIN-100 TABLETS (ACETYL SALICYLIC ACID 100MG) ( INV. QTY. 14532 PACK 10X30'S= 4359600 NOS ) | $43.2K | 1 |
| ALSIN -100 TAB LET ACETYL SALICYLIC ACID 100 MG. INV.QTY.14413 PACK 10 X 30S =4323900 NOS | $43.1K | 1 |
| ALSIN-100 TABLETS (ACETYL SALICYLIC ACID 100MG) (INV.QTY.14638 PACK 10X30'S= 4391400 NOS) | $42.2K | 1 |
| ALSIN-100 TABLETS (ACETYL SALICYLIC ACID 100MG) (INV.QTY.14592 PACK 10X30'S= 4377600 NOS) | $42.1K | 1 |
| ALSIN-100 TABLETS (ACETYL SALICYLIC ACID 100MG) ( INV. QTY. 14616 PACK 10X30'S= 4384800 NOS ) | $41.9K | 1 |
| ALSIN-100 TABLET ACETYL SALICYLIC ACID100 MG . INV.QTY.14196 PACK 10X30S=4258800 NOS | $41.7K | 1 |
| ALSIN-100 TABLET ACETYL SALICYLIC ACID100 MG . INV.QTY.14532 PACK 10X30S=4359600 NOS | $41.6K | 1 |
Cipla Limited exports 90 distinct Salicylic formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ASPIN 100 TABLETS (ACETYL SALICYLIC ACID with 8 shipments worth $113.6K.
How Does Cipla Limited Compare to Nearest Salicylic Exporters?
Exporters ranked immediately above and below #3 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | RECKITT BENCKISER (INDIA) PRIVATE LIMITED | $3.6M | 264 | 2 | $13.7K |
| 2 | RECKITT BENCKISER INDIA PRIVATE LIMITED | $2.2M | 86 | 1 | $25.6K |
| 3 | CIPLA LIMITED ★ | $2.0M | 121 | 3 | $16.3K |
| 5 | MEDREICH LIMITED | $1.0M | 77 | 9 | $13.2K |
| 6 | AUROBINDO PHARMA LTD | $745.3K | 40 | 2 | $18.6K |
Cipla Limited ranks #3 among 276 Indian Salicylic exporters. Average shipment value of $16.3K compared to the market average of $45.4K. The closest competitors by value are RECKITT BENCKISER (INDIA) PRIVATE LIMITED and RECKITT BENCKISER INDIA PRIVATE LIMITED.
Which Indian Ports Ship Salicylic Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 412 | 14.7% |
| BANGALORE ICD | 324 | 11.6% |
| DELHI AIR CARGO ACC (INDEL4) | 319 | 11.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 268 | 9.6% |
| DELHI AIR | 201 | 7.2% |
| NHAVA SHEVA SEA (INNSA1) | 134 | 4.8% |
| JNPT/ NHAVA SHEVA SEA | 111 | 4.0% |
| JNPT | 109 | 3.9% |
Geopolitical & Trade Policy Impact on Cipla Limited's Salicylic Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Salicylic, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Salicylic — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Salicylic shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 121 individual customs records matching Cipla Limited exporting Salicylic, covering 90 formulations to 4 countries via 7 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 132+ countries, 632+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Salicylic Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Salicylic exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Salicylic Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Salicylic. For current shipment-level data, contact TransData Nexus.